WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK) (known as MSD outside the United States and Canada) today announced that the U.S. Food and Drug Administration (FDA) has approved SYLATRON ...
The COMBI study, a prospective, open‐label, single‐arm phase 2 study ongoing in Denmark, is investigating the feasibility of treating patients with low- to intermediate-risk myelofibrosis ...
A chemically modified (pegylated*) form of interferon alfa-2b improves recurrence-free survival (RFS) in melanoma patients compared with observation alone, conclude authors of an Article in this ...
Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging PURPOSE: The efficacy of interferon alfa has been ...
To share our initial experience in the use of intralesional interferon alpha-2a at primary presentation in ocular surface tumours as a method of immunoreduction prior to definitive surgical management ...
Please provide your email address to receive an email when new articles are posted on . 38% of patients with cutaneous lupus erythematosus displayed evidence of positive interferon (IFN)-alpha ...
Abstract: Background: Using mathematical models, the pharmacodynamic properties of albinterferon alfa-2b (alb-IFN), a long-acting, recombinant protein comprising interferon alfa-2b genetically fused ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results